Is sofosbuvir and velpatasvir (Epclusa) harmful to the body?

The sofosbuvir and velpatasvir combination itself has been shown to be highly effective in clearing HCV from the blood of patients with normal liver function. Viral clearance was observed for all genotypes, including genotype3. Clearance was also very high in patients with abnormal liver function (Child-Pugh class B cirrhosis) when sofosbuvir and velpatasvir were combined with ribavirin. The combination of sofosbuvir and velpatasvir was well tolerated and safe. The European Medicines Agency believes the benefits of the sofosbuvir-velpatasvir combination outweigh its risks.

Long-term side effects have not been reported with sofosbuvir and velpatasvir combination. However, people with cirrhosis (scarring of the liver) may still experience symptoms of liver damage even after the hepatitis C virus has been cleared from the body. If you have cirrhosis, your doctor will want to monitor your liver function during and regularly after receiving treatment with sofosbuvir and velpatasvir combination. There have been reports of flu-like symptoms such as fatigue, muscle pain, sleep disturbance, and chills in people treated with the sofosbuvir-velpatasvir combination, and these side effects are likely caused by the body's recovery from the hepatitis C virus.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification (400mg+100mg)*28 tablets is priced at about 4,000 yuan per box. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The price of the specification (400mg + 100mg) * 28 tablets produced by Everest Pharmaceutical Factory in Bangladesh is about 850 yuan per box (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.